Enzolytics Inc. (ENZC)
USD 0.0
(7.69%)
USD 0.0
(7.69%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.17 Million USD | 25.99% |
| 2022 | -2.94 Million USD | -339.35% |
| 2021 | -669.48 Thousand USD | 80.77% |
| 2020 | -3.48 Million USD | -478.16% |
| 2019 | 920.42 Thousand USD | 152.36% |
| 2018 | -1.75 Million USD | -2968.55% |
| 2017 | -57.28 Thousand USD | 89.58% |
| 2016 | -549.59 Thousand USD | 89.11% |
| 2015 | -5.04 Million USD | 0.0% |
| 2010 | -7.51 Million USD | -674.8% |
| 2009 | -969.78 Thousand USD | -127.68% |
| 2008 | -425.94 Thousand USD | -1.03% |
| 2007 | -421.61 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -172.75 Thousand USD | 0.0% |
| 2024 Q2 | -1818.00 USD | 98.95% |
| 2023 Q3 | -2.27 Million USD | -86.41% |
| 2023 FY | -2.17 Million USD | 25.99% |
| 2023 Q1 | -427.55 Thousand USD | 71.67% |
| 2023 Q2 | -1.21 Million USD | -184.85% |
| 2022 Q2 | -224.19 Thousand USD | 73.45% |
| 2022 FY | -2.94 Million USD | -339.35% |
| 2022 Q4 | -1.5 Million USD | -297.07% |
| 2022 Q3 | -380.08 Thousand USD | -69.53% |
| 2022 Q1 | -844.59 Thousand USD | 0.0% |
| 2021 FY | -669.48 Thousand USD | 80.77% |
| 2021 Q1 | 204.5 Thousand USD | 101.84% |
| 2021 Q2 | -217.53 Thousand USD | -206.37% |
| 2021 Q3 | -388.58 Thousand USD | -78.63% |
| 2020 Q4 | -11.14 Million USD | 0.0% |
| 2020 FY | -3.48 Million USD | -478.16% |
| 2019 FY | 920.42 Thousand USD | 152.36% |
| 2018 FY | -1.75 Million USD | -2968.55% |
| 2017 FY | -57.28 Thousand USD | 89.58% |
| 2016 FY | -549.59 Thousand USD | 89.11% |
| 2015 FY | -5.04 Million USD | 0.0% |
| 2011 Q1 | -255.04 Thousand USD | 95.28% |
| 2011 Q2 | -221.24 Thousand USD | 13.25% |
| 2010 Q1 | -519.9 Thousand USD | 17.18% |
| 2010 FY | -7.51 Million USD | -674.8% |
| 2010 Q4 | -5.4 Million USD | -756.81% |
| 2010 Q3 | -631.23 Thousand USD | 33.86% |
| 2010 Q2 | -954.32 Thousand USD | -83.56% |
| 2009 Q3 | -197.13 Thousand USD | -134.88% |
| 2009 Q1 | -60.93 Thousand USD | 49.05% |
| 2009 Q2 | -83.93 Thousand USD | -37.73% |
| 2009 Q4 | -627.78 Thousand USD | -218.46% |
| 2009 FY | -969.78 Thousand USD | -127.68% |
| 2008 Q4 | -119.59 Thousand USD | 29.11% |
| 2008 Q2 | -18.1 Thousand USD | -2.84% |
| 2008 FY | -425.94 Thousand USD | -1.03% |
| 2008 Q3 | -168.7 Thousand USD | -832.09% |
| 2008 Q1 | -17.6 Thousand USD | 32.55% |
| 2007 Q3 | -1561.00 USD | 0.0% |
| 2007 FY | -421.61 Thousand USD | 0.0% |
| 2007 Q4 | -26.09 Thousand USD | -1571.68% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -63.006% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 68.826% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 104.109% |
| Nascent Biotech, Inc. | -2.08 Million USD | -4.27% |
| Rebus Holdings, Inc. | -1.02 Million USD | -113.415% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 103.342% |
| Qrons Inc. | -789.34 Thousand USD | -175.776% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -244.214% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 96.523% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -423.933% |
| Skye Bioscience, Inc. | -37.64 Million USD | 94.217% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 97.096% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 66.898% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -696.202% |
| SQZ Biotechnologies Company | -79.46 Million USD | 97.261% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 24.739% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -19.571% |
| Mesoblast Limited | -87.95 Million USD | 97.525% |
| Marizyme, Inc. | -65.34 Million USD | 96.669% |
| Genus plc | 7.9 Million USD | 127.555% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 80.014% |
| Pharming Group N.V. | -10.54 Million USD | 79.363% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -0.323% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 41.329% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 75.386% |
| ContraFect Corporation | -65.15 Million USD | 96.659% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 55.448% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -26.014% |
| IMV Inc. | -36.48 Million USD | 94.034% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 72.991% |
| MultiCell Technologies, Inc. | -380.07 USD | -572645.021% |
| ONE Bio Corp. | 8.67 Million USD | 125.089% |
| Accustem Sciences Inc. | -3.74 Million USD | 41.896% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 95.789% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -71.792% |
| Q BioMed Inc. | -2.05 Million USD | -6.079% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 41.687% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 8.57% |
| Biomind Labs Inc. | -1.21 Million USD | -79.264% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 96.355% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 29.82% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 72.456% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -11.675% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -14435.47% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 86.285% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 62.58% |
| GB Sciences, Inc. | -1.36 Million USD | -59.864% |
| Alpha Cognition Inc. | -13.77 Million USD | 84.194% |
| HST Global, Inc. | -146.21 Thousand USD | -1388.839% |
| CSL Limited | 2.64 Billion USD | 100.082% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -24.052% |
| Halberd Corporation | -79.67 Thousand USD | -2632.105% |
| Agentix Corp. | -1.37 Million USD | -58.406% |
| Resverlogix Corp. | -3.61 Million USD | 39.7% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 31.361% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.262% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 2321.257% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 131.436% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 45.209% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 28.066% |
| AVAX Technologies, Inc. | -6.41 Million USD | 66.059% |
| Zenith Capital Corp. | -10.59 Million USD | 79.456% |
| Genscript Biotech Corporation | -95.47 Million USD | 97.72% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -9265.941% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 47.495% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -3501.605% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -8.564% |
| Kadimastem Ltd | -3.3 Million USD | 34.183% |
| Helix BioMedix, Inc. | -1.05 Million USD | -106.128% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 43.0% |
| BioStem Technologies, Inc. | -8.48 Million USD | 74.339% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -393.2% |
| LadRx Corporation | 400.44 Thousand USD | 643.606% |
| Cell Source, Inc. | -5.32 Million USD | 59.091% |
| Regen BioPharma, Inc. | 1.02 Million USD | 312.683% |
| Regen BioPharma, Inc. | 1.02 Million USD | 312.683% |
| NovAccess Global Inc. | -4.76 Million USD | 54.356% |
| Affymax, Inc. | -14.42 Million USD | 84.908% |
| Itoco Inc. | -1.86 Million USD | -16.471% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 51.0% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -30.427% |
| Mobile Lads Corp. | -2.26 Million USD | 3.82% |
| CytoDyn Inc. | -49.84 Million USD | 95.632% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -2654.333% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -854.219% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -131.202% |
| SYBLEU INC | -180.3 Thousand USD | -1107.312% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -34.977% |
| International Stem Cell Corporation | -131 Thousand USD | -1561.704% |
| Bioxytran, Inc. | -4.28 Million USD | 49.139% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -3910.967% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 13.968% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 95.472% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -2.972% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -178.764% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 31.287% |
| Neutra Corp. | -233.46 Thousand USD | -832.402% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 89.272% |
| PureTech Health plc | -65.69 Million USD | 96.687% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 89.764% |
| IXICO plc | -1.17 Million USD | -84.79% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 78.072% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 96.19% |
| CSL Limited | 2.64 Billion USD | 100.082% |
| Cellectis S.A. | -103.17 Million USD | 97.89% |